Novel Spectacle Lenses for Near-sightedness

(CHERRY Trial)

Age: < 18

Sex: Any

Trial Phase: Academic

Sponsor: SightGlass Vision, Inc.

Disqualifiers: Common cold, active allergies, fatigue

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 3 years

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how new spectacle lenses might help manage near-sightedness (difficulty seeing far away). Researchers focus on how changes in the thickness of the choroid (a layer of blood vessels behind the retina) affect vision over time. Participants already in the CPRO-1802-001 study who have signed the necessary consent forms may be suitable candidates to join.

As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in vision care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that these novel spectacle lenses are safe for near-sightedness?

Research has shown that new glasses for nearsightedness (myopia) are safe for use. Studies have found them comfortable for extended wear. In one study, the glasses proved safe and effective for children with myopia over a year. Another study demonstrated their safety and ability to slow myopia progression over four years. These findings suggest that the glasses are generally safe, with no major side effects reported. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Unlike traditional glasses that simply correct vision by refocusing light onto the retina, the novel spectacle lenses for near-sightedness are designed to alter the way light is focused in the peripheral retina. This approach aims to slow down the progression of near-sightedness, or myopia, by addressing its underlying causes rather than just its symptoms. Researchers are excited about these lenses because they could potentially reduce the need for stronger prescriptions over time, offering a more sustainable and long-term solution for managing myopia.

What evidence suggests that these novel spectacle lenses are effective for near-sightedness?

Research has shown that new types of glasses can help slow the progression of near-sightedness (myopia). Studies have found that these special lenses significantly reduce both the elongation of the eye and the deterioration of vision compared to regular glasses. For instance, some lenses reduced myopia progression by 47%–69% in certain groups. One study found that these lenses slowed both eye growth and vision changes over a year. This evidence suggests that the lenses tested in this trial effectively manage and control myopia. ^{6 7 8 9 10}

Who Is on the Research Team?

Lyndon Jones, PhD, FCoptom

Principal Investigator

Centre for Ocular Research & Education, Canada

Jill Woods, BSc, MCOptom

Principal Investigator

Centre for Ocular Research & Education, Canada

Are You a Good Fit for This Trial?

This trial is for individuals already enrolled in the CPRO-1802-001 study who have near-sightedness, including degenerative or progressive myopia. Participants must be minors who've given their assent and whose parents or guardians have signed a consent letter. Those with temporary health issues affecting the eyes like colds, allergies, or fatigue cannot join.

Inclusion Criteria

Read and signed an Assent and their parent/guardian has signed an information consent letter

Participating in the CPRO-1802-001 (Cypress_SG) study at CORE

Exclusion Criteria

I currently have a temporary health issue affecting my eyes.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants wear novel spectacle lenses designed to inhibit myopia progression

3 years

Regular visits for choroidal thickness measurements and visual field assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Novel Spectacle Lens

Trial Overview

The study is testing a new type of spectacle lens designed to control the progression of myopia by examining changes in choroidal thickness (a layer at the back of the eye) throughout the day.

How Is the Trial Designed?

Group I: Treatment Experimental Treatment 1 Intervention

Subjects wearing novel spectacle lenses will be assessed

Who Is Running the Clinical Trial?

SightGlass Vision, Inc.

Lead Sponsor

Trials

11

Recruited

1,100+

University of Waterloo

Collaborator

Trials

132

Recruited

221,000+

Published Research Related to This Trial

Power-adjustable spectacle lenses utilizing the Alvarez-Lohmann principle offer a cost-effective solution for measuring and correcting refractive errors in vision.

A newly designed mechanical frame enhances the functionality of these lenses by allowing for adjustment of interpupillary distance, and it can be produced using affordable plastic injection molding techniques.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mechanical design of a power-adjustable spectacle lens frame. Zapata, A., Barbero, S.[2019]

The study involving 119 Vietnamese children showed that highly aspherical lenslet (HAL) spectacles significantly slowed myopia progression compared to conventional single vision (SV) spectacles, particularly during the second stage of the trial.

There was no evidence of myopia rebound when children switched from HAL to SV, indicating that HAL spectacles are a safe and effective option for managing myopia in children.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Spectacle Lenses With Highly Aspherical Lenslets for Slowing Myopia: A Randomized, Double-Blind, Cross-Over Clinical Trial: Parts of these data were presented as a poster at the Annual Research in Vision and Ophthalmology meeting, 2022. Sankaridurg, P., Weng, R., Tran, H., et al.[2023]

Citations

1.

ophthalmologyscience.org

ophthalmologyscience.org/article/S2666-9145(25)00238-6/fulltext

One-Year Myopia Control Efficacy of a New Defocus ...

The MYOGEN spectacle lenses significantly reduced myopia progression and axial elongation in schoolchildren compared with SVLs. The lenses ...

2.

bjo.bmj.com

bjo.bmj.com/content/early/2025/09/05/bjo-2025-327629

Efficacy of spectacle lenses for myopia control: a meta- ...

The pooled results demonstrated that myopia control spectacle lenses significantly reduced both AL elongation and spherical SER progression ...

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4696394/

Spectacle Lenses Designed to Reduce Progression of Myopia

We present data on the progression of myopia with novel spectacle lens designs that manipulate the curvature of the peripheral image shell while maintaining ...

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S1888429624000219

Real–world outcomes on myopia management efficacy of ...

Myopia control effect in DSDO group was 47%–69% and 33%–62% in DIMS group compared to historical SVS lenses. Conclusions. Both DSDO and DIMS spectacle lenses ...

5.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37690499/

Evaluating the Effect of a Myopia Control Spectacle Lens ...

Outcomes measured were changes in axial length and cycloplegic refraction as well as subjective rating of visual experience over a period of 12 months. Results: ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03623074

NCT03623074 | Control of Myopia Using Novel Spectacle ...

3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of ...

7.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/36126105/

Control of myopia using diffusion optics spectacle lenses

12-month results from this ongoing trial demonstrate the safety and effectiveness of DOT spectacles for reducing myopic progression.

8.

ophthalmologyscience.org

ophthalmologyscience.org/article/S2666-9145(25)00271-4/fulltext

MyopiaX-1 Safety and Efficacy of a Novel Approach to ...

MyopiaX was safe and well tolerated over 12 months in treatment-naive children with myopia. This exploratory study provides the first clinical ...

9.

reviewofmm.com

reviewofmm.com/how-safe-and-effective-are-next-generation-spectacle-lenses-for-myopia-management/

How Safe and Effective Are Next-Generation Spectacle ...

This article presents the safety and efficacy of five spectacle lenses: Hoya MiYOSMART, Essilor Stellest, Zeiss MyoCare, Rodenstock MyCon, and SightGlass ...

10.

bmjophth.bmj.com

bmjophth.bmj.com/content/9/1/e001790

Control of myopia using diffusion optics spectacle lenses

Conclusion DOT 0.2 spectacle lenses are safe and effective at reducing myopia progression, with additional benefit evident in year 4 of wear.